美股异动 | 礼来(LLY.US)终止PD-1激动剂候选药物研究 AnaptysBio(ANAB.US)暴跌超20%

智通财经网10-30

周三，AnaptysBio(ANAB.US)股价走低，截至发稿，该股跌超20%，报24.455美元。AnaptysBio正在推进一种与礼来(LLY.US)PD-1激动剂抗体Peresolimab类似的关节炎疗法，在礼来宣布决定终止对该候选药物的研究后，AnaptysBio股价大跌。今年7月，H.C. Wainwright首次覆盖AnaptysBio，给予“买入”评级和55美元的目标价。该行认为其...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2479825667?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-10-30 22:26","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2479825667","market":"sg","top_or_hot":-1,"title":"美股异动 | 礼来(LLY.US)终止PD-1激动剂候选药物研究 AnaptysBio(ANAB.US)暴跌超20%","media":"智通财经网","content":"<div>\n<p>周三，AnaptysBio(ANAB.US)股价走低，截至发稿，该股跌超20%，报24.455美元。AnaptysBio正在推进一种与礼来(LLY.US)PD-1激动剂抗体Peresolimab类似的关节炎疗法，在礼来宣布决定终止对该候选药物的研究后，AnaptysBio股价大跌。今年7月，H.C. Wainwright首次覆盖AnaptysBio，给予“买入”评级和55美元的目标价。该行认为其...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-10-30/doc-incukean0821980.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美股异动 | 礼来(LLY.US)终止PD-1激动剂候选药物研究 AnaptysBio(ANAB.US)暴跌超20%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美股异动 | 礼来(LLY.US)终止PD-1激动剂候选药物研究 AnaptysBio(ANAB.US)暴跌超20%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-30 22:26 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-10-30/doc-incukean0821980.shtml><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>周三，AnaptysBio(ANAB.US)股价走低，截至发稿，该股跌超20%，报24.455美元。AnaptysBio正在推进一种与礼来(LLY.US)PD-1激动剂抗体Peresolimab类似的关节炎疗法，在礼来宣布决定终止对该候选药物的研究后，AnaptysBio股价大跌。今年7月，H.C. Wainwright首次覆盖AnaptysBio，给予“买入”评级和55美元的目标价。该行认为其...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-10-30/doc-incukean0821980.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765059.SGD","symbol_name":"FTIF - Franklin US Opportunities A Acc SGD","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-10-30/doc-incukean0821980.shtml","article_id":"2479825667","we_media_id":null,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-10-30/doc-incukean0821980.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2479825667","pubTimestamp":1730298360,"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"周三，AnaptysBio(ANAB.US)股价走低，截至发稿，该股跌超20%，报24.455美元。AnaptysBio正在推进一种与礼来(LLY.US)PD-1激动剂抗体Peresolimab类似的关节炎疗法，在礼来宣布决定终止对该候选药物的研究后，AnaptysBio股价大跌。今年7月，H.C. Wainwright首次覆盖AnaptysBio，给予“买入”评级和55美元的目标价。该行认为其旗下的PD-1激动剂rosnilimab可能比peresolimab更有效。rosnilimab的试验初步数据预计将在2025年第一季度公布。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","BK4588":"碎股","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU0882574139.USD":"富达环球消费行业基金A ACC","ANAB":"Anaptysbio Inc","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4581":"高盛持仓","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","PD":"PagerDuty, Inc.","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0079474960.USD":"联博美国增长基金A","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","BK4516":"特朗普概念","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","BK4023":"应用软件","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU0058720904.USD":"联博国际健康护理基金A","BK4139":"生物科技","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LLY":"礼来","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV"},"translate_title":"U.S. stock changes Eli Lilly (LLY.US) terminates PD-1 agonist drug candidate research AnaptysBio (ANAB.US) plummets more than 20%","themeId":"69b555e67b9b57f18da6272607047169","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PD":1,"ANAB":1,"LLY":1},"content_text":"周三，AnaptysBio(ANAB.US)股价走低，截至发稿，该股跌超20%，报24.455美元。AnaptysBio正在推进一种与礼来(LLY.US)PD-1激动剂抗体Peresolimab类似的关节炎疗法，在礼来宣布决定终止对该候选药物的研究后，AnaptysBio股价大跌。今年7月，H.C. Wainwright首次覆盖AnaptysBio，给予“买入”评级和55美元的目标价。该行认为其旗下的PD-1激动剂rosnilimab可能比peresolimab更有效。rosnilimab的试验初步数据预计将在2025年第一季度公布。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479825667"}